The present invention includes a solid lyophilized form of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c] fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide. Furthermore, the present invention provides compositions comprising the solid lyophilized form, therapeutic use of the solid lyophilized forms, and the process of producing the solid lyophilized form.本發明包括2-(4-甲基-[1,4]二氮雜環庚烷-1-基)-5-側氧基-5H-7-硫雜-1,11b-二氮雜-苯并[c]茀-6-甲酸(5-甲基-吡嗪-2-基甲基)-醯胺之固體凍乾形式。此外,本發明提供包含該固體凍乾形式之組合物、該等固體凍乾形式之醫療用途,及製備該固體凍乾形式之方法。